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Abstract
Background—Metastatic castration-resistant prostate cancer (mCRPC) often involves bone, and 
bone-targeted therapy (BTT) has become part of the overall treatment strategy.
Objective—Investigation of outcomes for concomitant BTT in a post hoc analysis of the COU-
AA-302 trial, which demonstrated an overall clinical benefit of abiraterone acetate (AA) plus 
prednisone over placebo plus prednisone in asymptomatic or mildly symptomatic chemotherapy-
naïve mCRPC patients.
Design, setting, and participants—This report describes the third interim analysis 
(prespecified at 55% overall survival [OS] events) for the COU-AA-302 trial.
Intervention—Patients were grouped by concomitant BTT use or no BTT use.
Outcome measurements and statistical analysis—Radiographic progression-free survival 
and OS were coprimary end points. This report describes the third interim analysis (prespecified at 
55% OS events) and involves patients treated with or without concomitant BTT during the COU-
AA-302 study. Median follow-up for OS was 27.1 mo. Median time-to-event variables with 95% 
confidence intervals (CIs) were estimated using the Kaplan-Meier method. Adjusted hazard ratios 
(HRs), 95% CIs, and p values for concomitant BTT versus no BTT were obtained via Cox models.
Results and limitations—While the post hoc nature of the analysis is a limitation, superiority 
of AA and prednisone versus prednisone alone was demonstrated for clinical outcomes with or 
without BTT use. Compared with no BTT use, concomitant BTT significantly improved OS (HR 
0.75; p = 0.01) and increased the time to ECOG deterioration (HR 0.75; p < 0.001) and time to 
opiate use for cancer-related pain (HR 0.80; p = 0.036). The safety profile of concomitant BTT 
with AA was similar to that reported for AA in the overall intent-to-treat population. 
Osteonecrosis of the jaw (all grade 1/2) with concomitant BTT use was reported in <3% of 
patients.
Conclusions—AA with concomitant BTT was safe and well tolerated in men with 
chemotherapy-naïve mCRPC. The benefits of AA on clinical outcomes were increased with 
concomitant BTT.
Patient summary—Treatment of advanced prostate cancer often includes bone-targeted therapy. 
This post hoc analysis showed that in patients with advanced prostate cancer who were treated 
with abiraterone acetate and prednisone in combination with bone-targeted therapy, there was a 
continued trend in prolongation of life when compared with patients treated with prednisone alone.
Trial registration—ClinicalTrials.gov NCT00887198.
Keywords
Abiraterone acetate; Bone-targeted therapy; Chemotherapy-naïve; Metastatic castration-resistant 
prostate cancer
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1. Introduction
Prostate cancer is the second most commonly diagnosed malignancy in men, with a 5-yr 
prevalence estimate of 3 200 000 men worldwide [1]. In the USA, prostate cancer is the 
second leading cause of cancer-related death in men [2]. Most patients who present with 
metastatic disease at diagnosis or with disease recurrence after potentially curative therapy 
with prostatectomy or radiation therapy respond to castration with androgen deprivation 
therapy [3]; however, progression to castration-resistant disease usually occurs within 2–3 yr 
[3,4]. Ultimately, almost all patients who progress after androgen deprivation therapy 
develop metastatic castration-resistant prostate cancer (mCRPC) [3,4], and more than 90% 
of patients with mCRPC develop bone metastases, which produces significant morbidity in 
many men and is associated with increased mortality [5,6].
Bone-targeted therapy (BTT) delays the development of symptoms and reduces the risk of 
bone-specific morbidities [7–10]. The BTT agents bisphosphonates and denosumab inhibit 
osteoclast-mediated bone resorption and can prevent bone loss and increase bone mineral 
density in patients with prostate cancer receiving androgen deprivation therapy [10–12]. 
Zoledronic acid and denosumab are effective for the prevention of skeletal-related events in 
patients with metastatic prostate cancer [13]. Historically, bone-seeking 
radiopharmaceuticals have been used as a palliative treatment for pain in patients with 
metastatic prostate cancer [14]. Radium-223 was the first radiopharmaceutical agent shown 
to improve survival for symptomatic patients with mCRPC and no visceral disease, and was 
recently approved for this indication [15].
Abiraterone acetate is converted in vivo to abiraterone, which inhibits the enzyme 17α-
hydroxylase/C17,20-lyase and blocks extragonadal and testicular androgen biosynthesis, a 
key target for blocking tumor growth in mCRPC [16,17].
Study COU-AA-302 compared the efficacy and safety of abiraterone acetate plus low-dose 
prednisone (hereafter referred to as abiraterone) compared to prednisone alone in 
asymptomatic or mildly symptomatic men with chemotherapy-naïve mCRPC [20]. 
Abiraterone doubled time to radiographic progression-free survival (rPFS) compared to 
prednisone alone (median 16.5 vs 8.3 mo). All secondary endpoints significantly favored 
abiraterone over prednisone alone [20].
The third interim analysis (IA3) of study COU-AA-302 (56% of expected death events) 
confirmed that patients treated with abiraterone had a statistically significant improvement in 
rPFS (HR 0.52; p < 0.0001), The overall survival (OS) analysis favored abiraterone over 
prednisone alone (median 35.3 vs 30.1 mo, HR 0.79; p = 0.0151; prespecified statistical 
boundary α = 0.0035), and the OS benefit of abiraterone was supported in an exploratory 
multivariate analysis (HR 0.74; p = 0.0017) that adjusted for baseline prognostic factors 
[22]. In addition, analyses of prespecified measures of patient-reported outcomes confirmed 
that abiraterone treatment delayed pain progression and deterioration in functional status 
compared with prednisone alone [21,22]. The objective of the present post hoc analysis of 
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study COU-AA-302 was to evaluate the clinical benefits and safety of abiraterone and 
concomitant BTT in chemotherapy-naïve mCRPC patients.
2. Patients and methods
Study COU-AA-302 (NCT00887198) is a phase 3, multinational, randomized, double-blind, 
placebo-controlled study being conducted at 151 sites in 12 countries. Patients were enrolled 
from April 2009 to June 2010, and the study is ongoing. The ethics review boards at all 
participating institutions approved the study, and all patients gave written informed consent.
2.1 Study design
The study design and the primary and secondary efficacy endpoints have been described 
previously [20]. The study included male patients with mCRPC aged ≥18 yr who were 
medically or surgically castrated, had tumor progression, and were asymptomatic or mildly 
symptomatic. Patients with visceral metastases were excluded, as were patients who had 
received previous therapy with ketoconazole for >7 d.
Patients were randomized at a 1:1 ratio to receive abiraterone acetate 1 g daily and 
prednisone 5 mg twice daily (abiraterone group) or placebo and prednisone 5 mg twice daily 
(prednisone alone group) via a centralized interactive web/voice response system in this 
double-blind, placebo-controlled multinational study. A permuted block randomization was 
used. The treatment was in continuous 28-d cycles [20]. Patients were stratified by Eastern 
Cooperative Oncology Group performance status (ECOG PS) score (0 vs 1). Concomitant 
BTT use was defined as the use of at least one of the following classes of bone drugs during 
the study: bisphosphonate, RANKL inhibitor, radiopharmaceutical, or other bone-targeted 
agent. Patients had the first recorded dose of BTT in the study after randomization, and 
although new BTT was not allowed per protocol, 7% of patients treated with BTT were 
actually treated after study entry. The primary end point of rPFS was defined as time from 
randomization to radiographic progression, as previously described [20]. Secondary 
endpoints were time to prostate-specific antigen (PSA) progression according to Prostate 
Cancer Working Group 2 criteria, time to initiation of cytotoxic chemotherapy, time to 
opiate use for cancer-related pain, and time to deterioration in ECOG PS score by ≥1 point 
[23]. Adverse events (AEs) of special interest included events related to mineralocorticoid 
excess (hypertension, hypokalemia, fluid retention).
2.2. Statistical analyses
The present analyses represent IA3 data at 56% of expected death events. The medians for 
time-to-event variables with 95% confidence intervals (CIs) were estimated using the 
Kaplan-Meier method. Patients were grouped by concomitant BTT use or no BTT use. Since 
most patients who used concomitant BTT received it from study start (336/353, 95%), 
concomitant BTT use was treated as a baseline covariate. However, sensitivity analyses 
treating concomitant BTT use as time-dependent were also conducted and showed similar 
results. The adjusted HRs, 95% CIs, and p values for concomitant BTT use versus no BTT 
use were obtained through Cox models that also included treatment and key baseline factors 
(PSA, lactate dehydrogenase, alkaline phosphatase, hemoglobin, and whether a patient had 
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bone metastases only at entry) as covariates. The treatment effect on all endpoints within 
each subgroup was assessed using a stratified Cox regression model, and p values were 
determined by stratified log-rank test. No adjustment for multiple testing was made for this 
post hoc analysis; significance was declared for p ≤ 0.05.
3. Results
A total of 353 patients (34% [184/546] of the abiraterone group, 31% [169/542] of the 
prednisone group) were receiving concomitant BTT. Of these 353 patients, 93% were treated 
with zoledronic acid, 6% with denosumab, and the remaining 1% with other BTT. Among 
the 353 patients who received concomitant BTT, 336 (95%) were receiving BTT at baseline. 
Another 17 (5%) patients started BTT during the study. Baseline patient characteristics were 
generally similar among the treatment arms (Table 1). As expected, there was a higher 
prevalence of bone disease and a higher percentage of patients with a baseline Gleason score 
≥8 among patients with BTT use. In the BTT group, 93% (329/353) of patients had bone 
disease at study entry, with a median time of 4 yr from the time of initial diagnosis to first 
dose of the study drug. In the group without BTT use, 76% (555/735) of patients had bone 
disease at study start, with a median time of 6 yr from the time of initial diagnosis to first 
dose of study drug. BTT use in patients without bone disease at study start was compatible 
with the dosing used for bone loss prevention, not the level used for bone metastases. The 
primary and secondary endpoint results obtained at the time of the IA3 have been described 
in detail previously [22].
3.1. Effect of concomitant BTT use versus no BTT use
The effect of concomitant BTT use on clinical endpoints was evaluated using data from both 
treatment arms. The interaction effects of concomitant BTT use and treatment group were 
not statistically significant for any of the endpoints (Table 2; p = 0.13–1.0). Point estimates 
of HRs for all efficacy endpoints were <1.0. BTT use was associated with significantly 
longer OS (p = 0.012; risk reduction 25%), longer time to deterioration in ECOG PS (p < 
0.001, risk reduction 25%), and longer time to opiate use for cancer-related pain (p = 0.036, 
risk reduction 20%; Table 2). BTT use was not associated with significantly longer time to 
chemotherapy initiation or to PSA progression.
3.2. Subgroup analysis
Exploratory associations with clinical outcomes were evaluated within the subgroups of 
patients with and without BTT use. Favorable results for abiraterone were observed for all 
endpoints with or without BTT use, although statistical significance was not consistently 
achieved because of the reduced sample size in each subgroup (Table 3). The Kaplan-Meier 
data for time-to-event outcomes stratified by BTT use in each of the treatment arms illustrate 
the effect of BTT use and beneficial effects on OS, time to opiate use, and ECOG PS 
deterioration (Fig. 1).
3.3. Safety
As expected given the mechanisms of action of the drugs, the incidence of AEs observed for 
concomitant BTT was similar to that observed in the overall population [20] and in patients 
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without concomitant BTT (Table 4). Grade 3/4 AEs with or without BTT in the abiraterone 
and prednisone treatment subgroups were similar to those reported previously [20,22]. AEs 
of special interest were similar among treatment subgroups. In addition, grade 3 or 4 
mineralocorticoid-related AEs were similar across treatment subgroups. Increases in alanine 
aminotransferase were more common with abiraterone. Osteonecrosis of the jaw with 
concomitant BTT use was reported in <3% of patients across the treatment groups; all cases 
were grade 1/2. Hypocalcemia was observed in 12 patients across the treatment groups, 
including one report each of grade 3 or 4 hypocalcemia in the prednisone with BTT group 
and abiraterone without BTT.
4. Discussion
This post hoc analysis is the first to evaluate the association between BTT and clinical 
outcomes in patients receiving abiraterone versus prednisone alone for mCRPC. We 
demonstrate that concomitant administration of abiraterone and BTT appears to be safe and 
well tolerated, and that the efficacy of abiraterone is maintained with concomitant BTT, with 
a possible added benefit of delaying the need for opiates to control pain. Delaying symptoms 
from bone metastases as mCRPC progresses is central to therapeutic management [24]. 
Prostate cancer patients with bone metastases have a greater risk of skeletal morbidity, 
which can impair quality of life (QoL) [25]. The findings that concomitant BTT use was 
associated with improvements in OS, time to opiate use for cancer-related pain, and time to 
ECOG PS deterioration are clinically relevant in the context of the mCRPC patient 
population. In the present analysis, all treatment group comparisons favored abiraterone over 
prednisone alone, and concomitant BTT was associated with increased effectiveness of 
abiraterone regarding clinical outcomes. Abiraterone with or without BTT was associated 
with a beneficial effect on survival, time to opiate use for cancer-related pain, and time to 
ECOG PS deterioration. These findings support and corroborate the patient-reported QoL 
outcomes from study COU-AA-302, in which abiraterone delayed pain progression, pain 
interference, and health-related QoL degradation compared with prednisone alone [22,26], 
and the outcomes from study COU-AA-301, in which abiraterone delayed pain progression 
and time to the first skeletal-related event in men with mCRPC previously treated with 
docetaxel [27].
Among patients treated with abiraterone, BTT was associated with a longer time to ECOG 
PS deterioration. Compared with prednisone with BTT, abiraterone in combination with 
BTT delayed the median time to deterioration in ECOG PS by 3.9 mo. Patients receiving 
abiraterone in combination with BTT also had a longer time to treatment with cytotoxic 
chemotherapy, an observation that supports the findings of previous reports [20,22]. These 
associations are consistent with an interaction between abiraterone and BTT use that may 
benefit clinical outcomes. In fact there is accumulating preclinical and clinical evidence of a 
potential anticancer effect of bisphosphonates [13]. In a retrospective analysis of a phase 3 
clinical trial on zoledronic acid versus placebo, zoledronic acid–mediated normalization of 
bone markers was associated with improved survival in men with bone metastases from 
CRPC [28].
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A limitation of our post hoc analysis is that as a retrospective analysis it may not account for 
unknown variables that may have had an impact on outcomes. Among the 353 patients who 
received BTT, 93% were treated with zoledronic acid. Furthermore, BTT use was not 
randomized, and the treatment effect was evaluated in subgroups, resulting in smaller sample 
sizes. Thus, these results are hypothesis-generating and may not represent the effects or 
interactions of abiraterone and other types of BTT, such as RANKL inhibitors. However, 
this post hoc analysis was conducted from a prespecified interim analysis, and the 
association between BTT use and outcomes was evaluated in patient subgroups that were 
well balanced among treatment arms. Moreover, the sample size in the current analysis is 
similar to that reported in a retrospective analysis showing a significant delay in the median 
time to a second skeletal-related event with zoledronic acid versus placebo in 422 men with 
advanced prostate cancer [29].
Safety data indicate that, as expected, there was no additional toxicity associated with 
abiraterone in combination with BTT compared to abiraterone without BTT. AEs that were 
mechanism-based and secondary to mineralocorticoid excess resulting from 17α-
hydroxylase/C17,20-lyase blockade occurred at similar rates in patients with or without 
concomitant BTT. Moreover, treatment-emergent AEs, including those leading to treatment 
discontinuation or death, were similar across treatment subgroups.
5. Conclusions
The results of this post hoc analysis of study COU-AA-302 show that the safety profile of 
treatment with abiraterone plus prednisone or prednisone alone with concomitant BTT is 
similar to that without concomitant BTT in chemotherapy-naïve patients with mCRPC. 
Concomitant BTT use was associated with longer OS, time to opiate use for cancer-related 
pain, and time to ECOG PS deterioration. The abiraterone treatment effect was maintained 
with or without concomitant BTT use for all endpoints. Moreover, this post hoc analysis 
suggests an added clinical benefit of abiraterone in combination with BTT in reducing 
symptomatic progression.
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In patients with metastatic castration-resistant prostate cancer, treatment with abiraterone 
acetate and prednisone with concomitant bone-targeted therapy showed improved clinical 
benefit compared to prednisone alone, as measured by overall survival, time to 
deterioration of Eastern Cooperative Oncology Group performance status, and time to 
opiate use for cancer-related pain.
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Fig. 1. 
Kaplan-Meier estimates of (A) overall survival, (B) time to opiate use for cancer-related 
pain, and (C) time to deterioration in Eastern Cooperative Oncology Group (ECOG) 
performance status score by ≥1 point. AA = abiraterone acetate; BTT = bone-targeted 
therapy; CI = confidence interval; NE = not estimable; P = prednisone.
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Table 1
Baseline patient characteristics and covariates (intent-to-treat population)
Characteristic Abiraterone (n = 546) Prednisone (n = 542)
BTT (n = 184) No BTT (n = 362) BTT (n = 169) No BTT (n = 373)
Median age, yr (IQR) 70.0 (64.0–76.0) 71.0 (65.0–78.0) 70.0 (65.0–76.0) 70.0 (63.0–76.0)
Gleason score ≥8 at initial diagnosis, n/N 
(%)
95/167 (57) 168/321 (52) 89/157 (57) 165/351 (47)
Median PSA at study entry, ng/ml (IQR) 42.5 (16.4–128.2) 41.5 (16.1–110.4) 34.2 (11.3–91.9)a 39.1 (18.2–98.1)b
ECOG PS at study entry, n (%)
  0 or 1 184 (100) 361 (100) 169 (100) 373 (100)
  2 0 1 (0.3) 0 0
Extent of disease, n (%)
  Bone 172 (94) 280 (78) 157 (93) 275 (74)
  Soft tissue or nodec 76 (41) 191 (53) 58 (34) 213 (57)
  Other 2 (1) 2 (0.6) 1 (0.6) 6 (2)
Bone metastasis only at study entry, n (%) 100 (54) 138 (38) 95 (56) 147 (39)
Median alkaline phosphatase, IU/l (IQR) 91.5 (66.0–140.5) 94.0 (72.0–133.0) 91.0 (65.5–137.0)d 89.0 (69.0–139.0)e
Median lactate dehydrogenase, U/l (IQR) 192.0 (164.0–223.0)f 184.5 (160.0–207.5)g 187.0 (161.0–222.0)h 183.0 (165.0–210.0)i
BTT use, n (%)
  At baseline 170 (31) NA 157(29) NA
  New starts during study 14 (3) NA 12 (2) NA
Type of BTT, n (%)j
  Zoledronic acid 172 (32) NA 158 (29) NA
  Other bisphosphonates 7 (1) NA 8 (2) NA
  Denosumab 16 (3) NA 6 (1) NA
  Otherk 2 (0.4) NA 3 (0.6) NA
BTT = bone-targeted therapy; ECOG PS = Eastern Cooperative Oncology Group performance status; IQR = interquartile range; NA = not 
applicable; PSA = prostate-specific antigen.
a
n = 167;
b
n = 372.
c
Metastatic lesions other than liver or visceral metastases on computed tomography or magnetic resonance imaging. If lymph node metastasis was 
the only evidence of metastasis, it must be ?2 cm in diameter. Patients with visceral metastases were excluded.
d
n = 168;
e
n = 371;
f
n = 183;
g
n = 360;
h
n = 166;
i
n = 370.
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j
Patients could receive more than one BTT at the same time.
k
Methylsulfonylmethane, strontium ranelate.
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Table 2
Clinical outcomes for treatment with and without concomitant bone-targeted therapy (BTT)
BTT No BTT HR (95% CI)a p value
Median rPFS (mo) 13.6 11.0 0.86 (0.72–1.02) 0.08
Median overall survival (mo) NE 30.3 0.75 (0.60–0.94) 0.012
Median time to opiate use for CaRP (mo) NE 27.9 0.80 (0.65–0.99) 0.036
Median time to chemotherapy initiation (mo) 22.4 21.1 0.92 (0.76–1.10) 0.4
Median time to ECOG PS deterioration (mo) 14.3 11.1 0.75 (0.64–0.87) <0.001
Median time to PSA progression (mo) 8.3 8.3 0.88 (0.75–1.03) 0.11
CaRP = cancer-related pain; CI = confidence interval; ECOG PS = Eastern Cooperative Oncology Group performance status; HR = hazard ratio; 
NE = not estimable; PSA = prostate-specific antigen; rPFS = radiographic progression-free survival.
aStratified Cox model with concomitant BTT use, treatment, and key baseline parameters (PSA, lactate dehydrogenase, alkaline phosphatase, 
hemoglobin, and whether a patient had bone metastases only at entry) as factors. When the interaction effect of treatment and BTT use was 
included in the models, the p values were not significant (rPFS, p = 0.18; OS, p = 0.13; time to opiate use for Ca-RP, p = 1.0; time to chemotherapy 
initiation, p = 0.9; time to ECOG PS deterioration, p = 0.18; time to PSA progression, p = 0.8).
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Table 3
Comparison of clinical outcomes for different treatments within bone-targeted therapy subgroups using a 
stratified Cox model
Bone-target therapy No bone-targeted therapy
Abiraterone Prednisone Abiraterone Prednisone
Median rPFS (mo) 16.6 10.4 16.3 8.2
  Adjusted HR (95% CI) 0.63 (0.48–0.84) 0.48 (0.40–0.58)
  p valuea 0.001 <0.0001
Median overall survival (mo) NE 30.9 31.6 30.1
  Adjusted HR (95% CI) 0.71 (0.50–1.00) 0.84 (0.67–1.05)
  p value 0.050 0.13
Median time to opiate use for CaRP (mo) NE 26.1 NE 22.6
  Adjusted HR (95% CI) 0.74 (0.53–1.04) 0.70 (0.56–0.87)
  p valuea 0.078 0.001
Median time to chemotherapy initiation (mo) 27.1 17.5 26.1 16.7
  Adjusted HR (95% CI) 0.66 (0.49–0.89) 0.59 (0.48–0.72)
  p valuea 0.006 <0.0001
Median time to ECOG PS deterioration (mo) 15.7 11.8 11.8 10.2
  Adjusted HR (95% CI) 0.76 (0.59–0.97) 0.87 (0.74–1.02)
  p valuea 0.025 0.086
Median time to PSA progression (mo) 11.1 5.6 11.0 5.6
  Adjusted HR (95% CI) 0.54 (0.42–0.70) 0.50 (0.42–0.60)
  p valuea <0.0001 <0.0001
CaRP = cancer-related pain; CI = confidence interval; ECOG PS = Eastern Cooperative Oncology Group performance status; HR = hazard ratio; 
NE = not estimable; PSA = prostate-specific antigen; rPFS = radiographic progression-free survival.
aStratified log-rank test.
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